Research Topics
Genomes and Genes | J A BluestoneSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cellsQizhi Tang
University of California San Francisco Diabetes Center, University of California, San Francisco, CA 94143, USA
J Immunol 171:3348-52. 2003..CD28 maintains a stable pool of peripheral Tregs by both supporting their survival and promoting their self-renewal. CD28 engagement promotes survival by regulating IL-2 production by conventional T cells and CD25 expression on Tregs...- How do CD4+CD25+ regulatory T cells control autoimmunity?Jeffrey A Bluestone
University of California at San Francisco Diabetes Center, Department of Medicine, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, California 94143 0540, USA
Curr Opin Immunol 17:638-42. 2005..Recent in vivo analyses support a model in which Tregs directly or indirectly alter the activation and differentiation of pathogenic T cells through an effect on antigen presenting cells... 
Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD miceB Salomon
The Committee on Immunology, University of Chicago, Chicago, IL 60637, USA
J Exp Med 194:677-84. 2001..This model demonstrates that NOD mice have "cryptic" autoimmune defects that can polarize toward the nervous tissue after the selective disruption of CD28/B7-2 costimulatory pathway...
T regulatory cells in autoimmune diabetes: past challenges, future prospectsJeffrey A Bluestone
UCSF Diabetes Center, San Francisco, CA 94143, USA
J Clin Immunol 28:677-84. 2008..The development of type 1 diabetes in the NOD mouse strain it is a complex process that depends on a fine balance between pathogenic and regulatory pathways...- Natural versus adaptive regulatory T cellsJeffrey A Bluestone
Diabetes Research Center, University of California, San Francisco, California 94118, USA
Nat Rev Immunol 3:253-7. 2003..Here, we propose the existence of two subsets of CD4+ T(Reg) cells--natural and adaptive--that differ in terms of their development, specificity, mechanism of action and dependence on T-cell receptor and co-stimulatory signalling... - The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantationJ A Bluestone
Diabetes Center, Department of Medicine, University of California San Francisco, CA, USA
Am J Transplant 8:2086-96. 2008.... - Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cellsJeffrey A Bluestone
Diabetes Center, Department of Medicine, University of California, San Francisco, CA 94143 0540, USA
Proc Natl Acad Sci U S A 101:14622-6. 2004..Emphasis will be placed on approaches to exploit regulatory T cells either directly or through the use of anti-CD3 immunotherapy... - Genetics, pathogenesis and clinical interventions in type 1 diabetesJeffrey A Bluestone
Diabetes Center and the Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA
Nature 464:1293-300. 2010..Here we describe current progress, the challenges ahead and the new interventions that are being tested to address the unmet need for preventative or curative therapies... - The functional plasticity of T cell subsetsJeffrey A Bluestone
University of California, San Francisco Diabetes Center and Department of Medicine, University of California, San Francisco 513 Parnassus Avenue, Box 0540 HSW 1114, San Francisco, California 94143, USA
Nat Rev Immunol 9:811-6. 2009..Here, Nature Reviews Immunology asks four leaders in the field their thoughts on the functional plasticity of T cell subsets... - CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthmaP A Padrid
Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
Am J Respir Cell Mol Biol 18:453-62. 1998..mansoni-sensitized and airway-challenged mice, most likely due to attenuated secretion of Th2-type cytokines and increased secretion of Th1-type cytokines... - Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway diseaseA G Tesciuba
Committee on Immunology and Section of Pulmonary and Critical Care, Department of Medicine, and Ben May Institute for Cancer Research, University of Chicago, Chicago, IL, 60637, USA
J Immunol 167:1996-2003. 2001..Thus, blockade of ICOS signaling can significantly reduce airway inflammation without affecting Th2 differentiation in this model of allergic airway disease... - Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergyA D Wells
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6144, USA
J Clin Invest 108:895-903. 2001..Anergy may be induced either through a combination of CTLA-4 signaling and the failure of cell cycle progression, or through a proliferation-independent mechanism in which TCR ligation occurs in the absence of CD28... - Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated toleranceP Zhou
Section of Transplantation, Departments of Surgery, Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
J Immunol 165:5580-7. 2000..These data suggest that the balance of type 1 and type 2 T lymphocyte differentiation is not critical for acute rejection but influences the robust tolerance induced by CD28/B7 blockade in this model... - ICOS costimulation: It's not just for TH2 cells anymoreA I Sperling
Section of Pulmonary and Critical Care Medicine, Department of Medicine, and the Committee on Immunology, University of Chicago, Chicago, IL 60637, USA
Nat Immunol 2:573-4. 2001..A current paradigm has ICOS participating in TH2 costimulation. New data indicates ICOS regulates not only TH2 cells, but also TH1s... - In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferationK E Earle
Department of Medicine, UCSF Diabetes Center, University of California, Box 0540, 513 Parnassus Avenue, San Francisco, CA 94143-0540, USA
Clin Immunol 115:3-9. 2005..Treg expansion is a critical first step before consideration of Tregs as a therapeutic intervention in patients with autoimmune or graft-versus-host disease... - Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cellsHelene Bour-Jordan
UCSF Diabetes Center, University of California at San Francisco, San Francisco, California 94143, USA
J Clin Invest 114:979-87. 2004..Thus, elimination of Treg's results in diabetes even in the absence of costimulation, which suggests a need for alternative strategies for immunotherapeutic approaches... - Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signalBrian T Fife
UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, California, USA
Nat Immunol 10:1185-92. 2009..Blockade of the immunomodulatory receptor CTLA-4 did not alter T cell motility or abrogate tolerance. Thus, PD-1-PD-L1 interactions maintain peripheral tolerance by mechanisms fundamentally distinct from those of CTLA-4... - The NOD mouse: a model of immune dysregulationMark S Anderson
Diabetes Center, University of California, San Francisco, California 94143, USA
Annu Rev Immunol 23:447-85. 2005..The information gained from this highly relevant model of human disease will lead to potential therapies that may alter the development of the disease and its progression in patients with T1D... - Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic miceEmma L Masteller
Diabetes Center, Department of Medicine, University of California, San Francisco, CA 94143-0540, USA
J Immunol 175:3053-9. 2005..These results provide a direct demonstration of the presence of autoantigen-specific T(reg) in the natural setting that can be applied as therapeutics for organ-specific autoimmunity... - The Immune Tolerance Network at 10 years: tolerance research at the bedsideJeffrey A Bluestone
Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA
Nat Rev Immunol 10:797-803. 2010..ITN investigators have published more than 80 original research papers based on this work. This Timeline article summarizes the progress and challenges of clinical research in the ITN... - Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigenBirgit Knoechel
Department of Pathology, University of California, San Francisco, School of Medicine, CA 94143, USA
J Exp Med 202:1375-86. 2005..Thus, a peripheral T cell reaction to a systemic antigen goes through a phase of effector cell-mediated pathology followed by T reg cell-mediated recovery, and both require the growth factor IL-2... - Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic miceQizhi Tang
Diabetes Center, Department of Medicine, University of California, San Francisco 94143, USA
Nat Immunol 7:83-92. 2006..Such persistent T(reg) cell-dendritic cell contacts preceded the inhibition of T(H) cell activation by dendritic cells, supporting the idea that dendritic cells are central to T(reg) cell function in vivo... - Achieving antigen-specific tolerance in diabetes: regulating specificallyWei Chen
Naomi Berrie Diabetes Center and the Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Int Rev Immunol 24:287-305. 2005.... - Central role of defective interleukin-2 production in the triggering of islet autoimmune destructionQizhi Tang
Department of Surgery, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143 0540, USA
Immunity 28:687-97. 2008..Together, these results suggest intra-islet Treg cell dysfunction secondary to defective IL-2 production is a root cause of the progressive breakdown of self-tolerance and the development of diabetes in nonobese diabetic mice... - Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD miceCraig Meagher
Diabetes Center, University of California, San Francisco, CA 94143, USA
J Immunol 180:7793-803. 2008..CD28KO mice provides an excellent model for the study of disease pathogenesis and development of new therapies for human autoimmune pancreatitis... - Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment GroupJ B Matthews
Immune Tolerance Network, San Francisco, CA 94107, USA
Clin Exp Immunol 160:176-84. 2010.... - Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathwaysBrian T Fife
Department of Medicine, UCSF Diabetes Center, University of California, San Francisco, CA 94113, USA
Immunol Rev 224:166-82. 2008.... - T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system functionJonathan H Esensten
Diabetes Center and the Department of Medicine, University of California, San Francisco, 94143, USA
J Immunol 183:75-82. 2009..Thus, the absence of diabetes in the NOD.Tbx21(-/-) is due to intrinsic defects in both T cells and cells of the innate immune system paired with the relative preservation of regulatory T cell function... - Beta-cell replacement for type I diabetesPeter G Stock
Department of Surgery, Division of Transplantation, University of California, San Francisco, San Francisco, California 94143, USA
Annu Rev Med 55:133-56. 2004..Widespread application of islet transplantation will depend on further improvements in selective immunosuppression, development of immunologic tolerance, and finding new sources of beta cells... - CTLA-4 and tolerance: the biochemical point of viewShunsuke Chikuma
Diabetes Center, University of California at San Francisco, San Francisco, CA 94143-0540
Immunol Res 28:241-53. 2003..A model is proposed based on these observations, which proposes that CTLA-4 may, in fact, function under some circumstances in a ligand-independent manner... - Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetesEmma L Masteller
Diabetes Center, University of California, San Francisco, CA 94143, USA
J Immunol 171:5587-95. 2003..Anti-IL-10R therapy reversed the tolerogenic effects of the dimer. Thus, peptide I-A(g7) dimers induce tolerance of BDC2.5 TCR T cells through a combination of the induction of clonal anergy and anti-inflammatory cytokines... - CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivoQizhi Tang
Diabetes Center and Department of Medicine, University of California, San Francisco, CA 94143, USA
J Immunol 170:1510-6. 2003.... - TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ TregsBrygida Bisikirska
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Clin Invest 115:2904-13. 2005..Foxp3 was also induced on CD8+ T cells in patients during mAb treatment, which suggests a potential mechanism of the anti-CD3 mAb immune modulatory effects involving induction of a subset of regulatory CD8+ T cells... - Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic miceHelene Bour-Jordan
University of California, San Francisco UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, CA 94143, USA
J Immunol 175:5649-55. 2005..Thus, there are sharp contrasts in the pathogenesis of autoimmune diseases targeting different tissues in the same NOD background... - Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonistBrian T Fife
UCSF Diabetes Center, Department of Medicine, UCSF, San Francisco, California 94143, and Department of Internal Medicine, Division of Nephrology, Mayo Clinic, Rochester, Minnesota, USA
J Clin Invest 116:2252-61. 2006.... - Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunityXuyu Zhou
Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA
J Exp Med 205:1983-91. 2008..These results support a central role for miRNAs in maintaining the stability of differentiated T reg cell function in vivo and homeostasis of the adaptive immune system... - Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathwayBrian T Fife
UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, and Transplantation Research Center, Brigham and Women s Hospital, Boston, MA 02115, USA
J Exp Med 203:2737-47. 2006.... - Sensory neurons link the nervous system and autoimmune diabetesHelene Bour-Jordan
UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143, USA
Cell 127:1097-9. 2006..In this issue of Cell, propose that a defect in a subset of sensory neurons innervating the pancreas plays a major role in initiating the chain of events that will lead to local inflammation, islet destruction, and autoimmune diabetes... - Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouseHelene Bour-Jordan
University of California, San Francisco Diabetes Center, Department of Medicine, CA 94143, USA
J Immunol 179:1004-12. 2007.... - Is antigen specificity of autoreactive T cells the key to islet entry?Cristina Penaranda
Department of Medicine, Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA
Immunity 31:534-6. 2009..In this issue of Immunity, Lennon et al. (2009) demonstrate that islet-antigen specificity is required for accumulation in the islets... - Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organsCristina Penaranda
Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, California, USA
Diabetes 59:1461-8. 2010..In this study, we address the role of tertiary lymphoid organs (TLOs) that form in the pancreas of NOD mice during disease progression... - The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cellsElisa Boden
UCSF Diabetes Center, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, HSW Room 1114, San Francisco, CA 94143-0540, USA
Novartis Found Symp 252:55-63; discussion 63-6, 106-14. 2003..Thus, clinical application of co-stimulatory blockade using agents such as CTLA4Ig in the treatment of autoimmune disease may result in complicated outcomes... - Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell functionQizhi Tang
UCSF Diabetes Center, University of California San Francisco, San Francisco, CA 94143 0540, USA
Eur J Immunol 34:2996-3005. 2004..These results help explain contradictions in the literature and support the existence of functionally distinct Treg... - CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospectsS M Kang
Transplantation Division, Department of Surgery, University of California, San Francisco, CA, USA
Am J Transplant 7:1457-63. 2007.... - CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocinK C Herold
Department of Medicine, University of Illinois at Chicago, 60612, USA
J Immunol 158:984-91. 1997..CD80 and CD86 molecules, the CD28/CTLA4 ligands, may have different roles in regulation of the disease and affect T cell function at steps beyond differentiation into mature phenotypes... - Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumabA M Posselt
Transplant Surgery, University of California, San Francisco, CA, USA
Am J Transplant 10:1870-80. 2010..Such an approach may minimize renal and islet toxicity and thus further improve long-term islet allograft survival... - The Immune Tolerance Network: tolerance at the crossroadsJ A Bluestone
Immune Tolerance Network, University of California, San Francisco, 513 Parnossus Avenue, Box 0540 HSW Room 1114, San Francisco, CA 94143 0540, USA
Philos Trans R Soc Lond B Biol Sci 356:773-6. 2001..This work has been funded by the National Institutes of Health (in collaboration with the Juvenile Diabetes Foundation International)... - Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinasesE Chuang
Gwen Knapp Center for Lupus and Immunology Research, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
J Immunol 162:1270-7. 1999..The association of CTLA-4 with Src kinases and with SHP-2 results in the formation of a CTLA-4 complex with the potential to regulate T cell activation... - Human regulatory T cells: role in autoimmune disease and therapeutic opportunitiesTodd M Brusko
Diabetes Center, University of California, San Francisco, CA 94143 0540, USA
Immunol Rev 223:371-90. 2008..In summary, the review provides an in-depth analysis and highlights the challenges and opportunities for immune intervention with Treg-based therapeutics... - Immunotherapy of insulin-dependent diabetes mellitusEmma L Masteller
UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, CA 94143, USA
Curr Opin Immunol 14:652-9. 2002..Several of these approaches employing monoclonal antibodies against the TCR-CD3 complex or soluble peptide antigens are producing favorable results in the clinic... - In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetesQizhi Tang
UCSF Diabetes Center, University of California San Francisco, 94143, USA
J Exp Med 199:1455-65. 2004..Most significantly, small numbers of antigen-specific Tregs can reverse diabetes after disease onset, suggesting a novel approach to cellular immunotherapy for autoimmunity... - B cell depletion: a novel therapy for autoimmune diabetes?Helene Bour-Jordan
Diabetes Center, Department of Medicine, UCSF, San Francisco, California 94143 0540, USA
J Clin Invest 117:3642-5. 2007..Although many questions remain unanswered, this mouse model represents the first opportunity to evaluate the potential value of rituximab as a novel therapy for autoimmune diabetes... - Regulatory T-cell physiology and application to treat autoimmunityQizhi Tang
UCSF Diabetes Center, Department of Medicine and Department of Pathology, University of California, San Francisco, CA 94143-0540, USA
Immunol Rev 212:217-37. 2006.... - The Src family kinase Fyn mediates signals induced by TCR antagonistsQizhi Tang
The Diabetes Center, University of California, San Francisco, CA 94143, USA
J Immunol 168:4480-7. 2002..Overexpression of Fyn, but not Lck, restored the mitogenicity of FcR nonbinding anti-CD3 in primary T cells. Taken together, these results suggest that Fyn mediates the partial signaling induced by TCR antagonists... - Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in miceMark A Travis
Lung Biology Center, Department of Medicine, University of California San Francisco, 1550 4th Street, Room 545, San Francisco, California 94158, USA
Nature 449:361-5. 2007.... - A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathyCedric Louvet
Diabetes Center and the Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
J Exp Med 206:507-14. 2009..Collectively, our data suggest that myelin P0 is a major autoantigen in autoimmune peripheral neuropathy... - CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitmentHelene Bour-Jordan
UCSF Diabetes Center and Department of Medicine, University of California San Francisco, 94143, USA
Nat Immunol 4:182-8. 2003..These results suggest that CTLA-4 has a critical role in T cell differentiation and that STAT6-dependent T(H)2 lineage commitment and stabilization can be bypassed by increasing the strength of signaling through the T cell receptor... - Impairment of NK cell function by NKG2D modulation in NOD miceKouetsu Ogasawara
Department of Microbiology and Immunology, University of California San Francisco, 513 Parnassus Avenue HSE 420, Box 0414, San Francisco, CA 94143, USA
Immunity 18:41-51. 2003..Modulation of NKG2D was mostly dependent on the YxxM motif of DAP10, the NKG2D-associated adaptor that activates phosphoinositide 3 kinase. These results suggest that NK cells may be desensitized by exposure to NKG2D ligands... - Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulationK C Herold
Department of Medicine, The University of Illinois at Chicago, 60612, USA
J Immunol 159:4150-3. 1997..Thus, CD28 costimulation may amplify an immune response by stimulating T cell survival, proliferation, and production of chemokines that recruit T cells to inflammatory sites... - Regulatory T cells as therapeutic targets in rheumatoid arthritisJonathan H Esensten
Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA
Nat Rev Rheumatol 5:560-5. 2009..Thus, cell-based therapy with TREG has the potential to produce durable disease remission in patients with RA... - Plasticity of CD4(+) FoxP3(+) T cellsXuyu Zhou
Diabetes Center and the Department of Medicine, University of California, San Francisco, CA 94143, USA
Curr Opin Immunol 21:281-5. 2009..The presence of these 'exTregs' in multiple inflammatory settings suggests a potential role for these cells in a variety of disease settings ranging from autoimmunity to cancer and infectious disease... - Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivoXuyu Zhou
Diabetes Center and the Department of Medicine, University of California, San Francisco, California, USA
Nat Immunol 10:1000-7. 2009..Thus, the generation of potentially autoreactive effector T cells as a consequence of Foxp3 instability has important implications for understanding autoimmune disease pathogenesis... - Inability to induce tolerance through direct antigen presentationIngrid C Rulifson
UCSF Diabetes Center, University of California, San Francisco 94143-0540, USA
Am J Transplant 2:510-9. 2002.... - Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cellsHelene Bour-Jordan
UCSF Diabetes Center, University of California at San Francisco, San Francisco, CA, USA
Immunol Rev 229:41-66. 2009..In this review, we discuss the connections between costimulation and Tregs that have changed the costimulation paradigm... - Expansion of human regulatory T-cells from patients with type 1 diabetesAmy L Putnam
Diabetes Center at the University of California, San Francisco UCSF, San Francisco, California, USA
Diabetes 58:652-62. 2009..However, translating Treg-based therapies from animal models of autoimmunity to human clinical trials requires robust methods for the isolation and expansion of these cells-a need forming the basis for these studies... - Small RNA regulators of T cell-mediated autoimmunityLukas T Jeker
Diabetes Center and the Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
J Clin Immunol 30:347-57. 2010..Where available, we refer to clinical correlations. Finally, we speculate how emerging knowledge about miRNA function in the immune system might be used diagnostically and therapeutically... - The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patientsMaureen A Su
Department of Pediatrics, University of California, San Francisco, CA 94143, USA
Clin Immunol 131:139-44. 2009..These findings suggest that the autoimmune predisposition in Turner Syndrome is not due to alterations in regulatory T cells but may be associated with a change in the proportion of T cell subsets... - Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic miceCedric Louvet
Diabetes Center and the Department of Medicine, University of California, San Francisco, CA 94143, USA
Proc Natl Acad Sci U S A 105:18895-900. 2008..Thus, long-term efficacy and tolerance is likely to depend on inhibiting a combination of tyrosine kinases supporting the use of selective kinase inhibitors as a new, potentially very attractive approach for the treatment of T1D... - Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4Shunsuke Chikuma
Diabetes Center, University of California at San Francisco, San Francisco, CA 94143, USA
J Exp Med 197:129-35. 2003..These results suggest that CTLA-4 functions to regulate T cell signaling by controlling TCR accumulation and/or retention within this a critical component of the immunological synapse... - CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cellsWeihong Liu
UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
J Exp Med 203:1701-11. 2006..Finally, we show that CD127 can be used to quantitate T reg cell subsets in individuals with type 1 diabetes supporting the use of CD127 as a biomarker for human T reg cells... - CTLA4Ig: bridging the basic immunology with clinical applicationJeffrey A Bluestone
Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA
Immunity 24:233-8. 2006..Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside... - NKG2D blockade prevents autoimmune diabetes in NOD miceKouetsu Ogasawara
Department of Microbiology and Immunology and the Cancer Research Institute, HSE 1001, Box 0414, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
Immunity 20:757-67. 2004..These findings demonstrate that NKG2D is essential for disease progression and suggest a new therapeutic target for autoimmune type I diabetes... - Notch 1 signaling regulates peripheral T cell activationTodd N Eagar
Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, CA 94143 USA
Immunity 20:407-15. 2004..Similar effects were observed in vivo in an adoptive transfer model. Therefore, Notch 1 signaling may play an important role in regulating naive T cell activation and homeostasis... - B7-independent inhibition of T cells by CTLA-4Shunsuke Chikuma
University of California at San Francisco Diabetes Center and Department of Medicine, University of California, San Francisco, CA 94143, USA
J Immunol 175:177-81. 2005..These results suggest that ligand binding is not essential for the CTLA-4 function and supports an essential role for CTLA-4 signaling during T cell activation... - Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative diseaseShunsuke Chikuma
UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, CA 94143 0450, USA
Eur J Immunol 37:1285-9. 2007..These results suggest common attributes of both diseases, but expression of both CTLA-4 and FoxP3 on the same cell subset is essential to fully prevent LP disease... - A comprehensive review of interventions in the NOD mouse and implications for translationLisl K M Shoda
Entelos Inc, Foster City, California 94404, USA
Immunity 23:115-26. 2005.... - TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetesMeriam Belghith
INSERM U580, IRNEM, Hopital Necker, 161 rue de Sevres, 75015 Paris, France
Nat Med 9:1202-8. 2003..These data explain the intriguing tolerogenic effect of CD3-specific antibodies and position them as the first clinically applicable pharmacological stimulant of TGF-beta-producing regulatory CD4+ T cells... - The role of CTLA-4 in induction and maintenance of peripheral T cell toleranceTodd N Eagar
Department of Microbiology Immunology and Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL 60611, USA
Eur J Immunol 32:972-81. 2002.... - Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala)Kevan C Herold
Naomi Berrie Diabetes Center, Department of Medicine and Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Clin Invest 111:409-18. 2003..It leads to the generation of T cells that might inhibit the autoimmune response and may be involved in the beneficial effect on beta cell destruction in Type 1 diabetes... - Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivoJelena S Bezbradica
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
J Immunol 174:4696-705. 2005..Thus, the differential immune outcome based on the type of APC that displays glycolipid Ags in vivo has implications for the design of therapies that harness the immunoregulatory functions of iNKT cells... - Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitisAdam P Kohm
Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL 60611, USA
J Immunol 174:4525-34. 2005.... - Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetesValeria Judkowski
Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA
Clin Immunol 113:29-37. 2004..5 T cells results in protection from disease. These results suggest that high affinity peptide analogues of autoimmune epitopes might be useful as therapeutic modulators in active autoimmune disease... - CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell toleranceTodd N Eagar
Department of Microbiology Immunology and Interdepartmental Immunobiology Center, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, IL 60611, USA
J Immunol 172:7442-50. 2004..This unresponsiveness was reversible by treatment with anti-CTLA-4 mAb. These results are consistent with the hypothesis that Ag-SP injection induces a state of T cell anergy that is maintained by CTLA-4 engagement... - A peptide of glutamic acid decarboxylase 65 can recruit and expand a diabetogenic T cell clone, BDC2.5, in the pancreasYang D Dai
Division of Immune Regulation, Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA
J Immunol 175:3621-7. 2005..5 cells in the pancreas has been observed, presumably due to tolerance induction. These data suggest that unique and/or altered processing of self Ags may play an essential role in the development and expansion of autoreactive T cells... - Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibodyBernhard J Hering
Diabetes Institute for Immunology and Transplantation, Department of Surgery, University of Minnesota, Minneapolis, MN, USA
Am J Transplant 4:390-401. 2004..Our preliminary results thus suggest that a combination of maximized viable islet yield, pretransplant islet culture, and preemptive immunosuppression can result in successful single-donor islet transplants... - When ligand becomes receptor--tolerance via B7 signaling on DCsErik B Finger
Nat Immunol 3:1056-7. 2002 - Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cellsNicole A Sherry
Department of Immunobiology, Yale University, New Haven, CT 06520, USA
Endocrinology 148:5136-44. 2007..This combinatorial approach may be useful in treatment of patients with new-onset T1DM... - Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cellsKwang Woo Hwang
Department of Medicine and Committee in Immunology, University of Chicago, Chicago, IL 60637, USA
J Immunol 169:633-7. 2002..Furthermore, CTLA-4(+/+) T cells that had encountered 7M-expressing tumors in vivo acquired defects in cytokine production and cytotoxicity. Thus, deliberate ligation of CTLA-4 in vivo potently inhibits allogeneic T cell responses... - Mechanisms of PDL1-mediated regulation of autoimmune diabetesIndira Guleria
Transplantation Research Center, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
Clin Immunol 125:16-25. 2007..These data provide strong evidence that PDL1 regulates autoimmune diabetes by limiting the expansion of CD4+ and CD8+ autoreactive T cells, and define the timing and locale of PDL1-mediated regulation of type 1 diabetes... - Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatmentSylvaine You
Universite Paris Descartes, 75015 Paris, France
Proc Natl Acad Sci U S A 104:6335-40. 2007.... - CD3-specific antibodies: a portal to the treatment of autoimmunityLucienne Chatenoud
Universite Rene Descartes, Paris 5, Institut National de la Sante et de la Recherche Medicale, Unité 580, Hopital Necker Enfants Malades, 161 rue de Sèvres 75743 Paris CEDEX 15, France
Nat Rev Immunol 7:622-32. 2007..This Review summarizes the pre-clinical and clinical studies of CD3-specific monoclonal antibody therapy and highlights future opportunities to enhance the efficacy of this potent immunotherapeutic... - CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cellsSylvain Perruche
Mucosal Immunology Unit, Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research NIDCR, US National Institutes of Health NIH, 30 Convent Drive, Bethesda, Maryland 20892, USA
Nat Med 14:528-35. 2008..Thus, CD3-specific antibody-induced immune tolerance is associated with TGF-beta production in phagocytes involved in clearing apoptotic T cells, which suggests that apoptosis is linked to active suppression in immune tolerance... - Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitusKevan C Herold
Naomi Berrie Diabetes Center and the Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York 10032, USA
N Engl J Med 346:1692-8. 2002..Preclinical studies suggested that a monoclonal antibody against CD3 could reverse hyperglycemia at presentation and induce tolerance to recurrent disease... - The immune tolerance network: a new paradigm for developing tolerance-inducing therapiesDaniel Rotrosen
National Institute of Allergy and Infectious Diseases, Bethesda, MD 20817, USA
J Allergy Clin Immunol 110:17-23. 2002..This report summarizes the rationale for emphasizing clinical research on immune tolerance and highlights the progress of the ITN... - An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in miceKarin Loser
Department of Dermatology, University of Munster, Munster, Germany
J Immunol 174:5298-305. 2005..Furthermore, CD86-mediated costimulation appears to play a more critical role in the protection against photocarcinogenesis than CD80... - Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled studyVicki Seyfert-Margolis
Immune Teolerance Network, Bethesda, Maryland, USA
Diabetes 55:2588-94. 2006..They may be useful for assessment of cellular autoimmune responses involved in type 1 diabetes... - Innate immunity and intestinal microbiota in the development of Type 1 diabetesLi Wen
Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Nature 455:1109-13. 2008..Together, these findings indicate that interaction of the intestinal microbes with the innate immune system is a critical epigenetic factor modifying T1D predisposition... - Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship?Qizhi Tang
Nat Immunol 7:551-3. 2006 - What does the future hold for cell-based tolerogenic therapy?Jeffrey A Bluestone
Immune Tolerance Network and of the Diabetes Center at the University of California, USA
Nat Rev Immunol 7:650-4. 2007....
Research Grants
- Conf on Mechanism and Applications of Immune ToleranceJeffrey Bluestone; Fiscal Year: 2002..Finally, specific talks in immunotherapy of autoimmunity, transplantation, cancer and infectious disease will be included. ..
- Role of Notch 1 in Immune ToleranceJeffrey Bluestone; Fiscal Year: 2005..To Identify the biochemical, cellular and genetic effects of Notch signaling in T cells; and Specific Aim #2. In vivo application of Notch signaling for the establishment of peripheral T cell tolerance. ..
- IMMUNOMODULATION OF TRANSPLANT REJECTION BY ANTI-CD3 MABJeffrey Bluestone; Fiscal Year: 2007..3) Use biochemical analyses and retroviral gene transfer to define the distal signaling events associated with clonal inactivation, cell death, and T helper subset differentiation induced by 2C11-IgG3. ..